AlphAIalphai — Financial news for AI agents
massdevice.comAUG 274 min read$ABT

Abbott’s next-generation Amulet LAA occlusion device earns CE Mark

Abbott (NYSE: ABT) announced its Amulet 360 left atrial appendage occlusion device received CE Mark. The device, designed to reduce stroke risk in AFib patients, features dual-seal technology and improved conformability. A 400-patient study showed 99.8% successful implantation and 94% complete LAA closure. The device is now available in Europe and under investigation in the US.

Original reporting
massdevice.com
Published Aug 27, 2026, 4:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Abbott’s next-generation Amulet LAA occlusion device earns CE Mark — source image
Source · massdevice.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

Regulatory clearance in Europe plus reported high implantation success and closure rates can shift expectations for device uptake and future revenue contribution, especially as Abbott begins expanding use beyond initial cases.

02

Market read

A CE Mark milestone with specific pivotal-study performance metrics and an immediate Europe rollout plan is a concrete catalyst for ABT’s medtech device narrative.

03

What to watch

The article notes Amulet 360 is investigational in the US, so upside may be more Europe-weighted initially; traders may also discount the impact until post-launch utilization data emerges.

Relevance 8/10Novelty 8/10Timing: today’s CE Mark announcement, with first European cases already completed

Background

Amulet 360 is Abbott’s next-generation left atrial appendage occlusion device for non-valvular AFib, designed to reduce stroke risk by sealing the LAA.

Company-level read

Ticker impact

$ABTBullishMedium confidence
Context

Abbott says its next-generation Amulet 360 LAA occlusion device received CE Mark, enabling European expansion after a 400-patient pivotal study.

Expected impact

Near-term upside bias for ABT on device-commercialization optimism, with follow-through dependent on uptake and any US trial/approval timeline.

Evidence & confidence

The article is a primary regulatory milestone with specific efficacy/safety metrics and an explicit plan to expand use across Europe in coming weeks.

Market effects

Sector

Supports the broader LAA occlusion and structural heart device competitive narrative, potentially raising expectations for minimally invasive stroke-prevention tech.

Regional

Improves near-term commercialization prospects in Europe as Abbott plans to expand Amulet 360 use across the region.

Global

May influence global medtech sentiment around regulatory pathways and adoption of next-gen stroke-prevention devices, though US remains investigational per the article.

Counterpoint

What could challenge this read

CE Mark does not guarantee rapid procedure volumes; real-world adoption, reimbursement, and physician learning curves may lag the pivotal-study results.

Key entities

  • company
    Abbott

    Received CE Mark for Amulet 360 and plans to expand European use in coming weeks.

  • product
    Amulet 360

    Next-generation minimally invasive LAA occlusion device with redesigned dual-seal technology.

  • product
    Amplatzer Amulet

    Abbott’s previous-generation LAA device referenced as the comparison baseline.

Read at source← All news

Related articles

AUG 27
$ABTMedAI 8/10

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten

Abbott (NYSE:ABT) received FDA authorization for Libre Duo, the first wearable to monitor glucose and ketones. The company plans a U.S. launch in 2026, targeting 8 million users. Abbott's stock is down 11% year-to-date, while competitor Dexcom (NASDAQ:DXCM) is up 34%. Abbott trades at a forward P/E of 21x with a $120.20 analyst target. Reimbursement expansion could drive growth, according to CEO Robert Ford.

aol.com2 min
AUG 26
$ABTMedAI 8/10

Abbott Receives CE Mark for Dissolving Stent

Abbott received CE Mark approval in Europe for its Esprit BTK System, a dissolvable stent for peripheral artery disease (PAD) below the knee. The system, which delivers everolimus, is designed to open arteries and dissolve over time. Clinical data showed a 48% reduction in repeat procedures compared to balloon angioplasty. Abbott aims to improve treatment options for PAD, a condition affecting 50 million Europeans.

dicardiology.com2 min
AUG 26
$ABTHighAI 9/10

FDA authorises Abbott’s Libre Duo dual glucose-ketone sensor

Abbott (ABT) received FDA authorization for its Libre Duo 10 Day, a dual glucose-ketone sensor. The device is the first of its kind and is designed for people aged two and older. Abbott shares closed at $115.82 on 26 August, up 10.86% over 20 trading days. The company plans to launch the product in the US later in 2026, with compatibility for insulin pump systems from Beta Bionics and Sequel Med Tech. Medtronic's MiniMed unit (MMED) is also developing similar technology. Abbott reported $11.16bn

financial-news.co.uk2 min
AUG 26
$ABTMed

Abbott secures CE mark for longer

Abbott received CE-mark approval for its 76mm Esprit BTK system to treat chronic limb-threatening ischaemia (CLTI). The longer-length device addresses the need to treat extensive below-the-knee lesions with fewer scaffolds, reducing procedural complexity. Abbott claims it is the only dissolving resorbable scaffold with robust long-term clinical evidence. The company sees this as an advancement for physicians in Europe, offering a solution for complex CLTI cases.

vascularnews.com1 min
AUG 26
$ABTHighAI 9/10

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Abbott Laboratories (N

The FDA approved Abbott's Libre Duo 10 Day, the first wearable device to monitor both glucose and ketones continuously. The system, for diabetes patients aged 2+, received De Novo approval after clinical trials. Abbott plans integrations with insulin pumps from Beta Bionics, Sequel Med Tech, Insulet, Tandem Diabetes, and Medtronic by 2027. ABT shares rose 0.32% to $116.30. Analysts note potential competition with DexCom.

benzinga.com3 min